|
1
|
Sørlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey
SS, et al: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dent R, Trudeau M, Pritchard KI, Hanna WM,
Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA:
Triple-negative breast cancer: Clinical features and patterns of
recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bosch A, Eroles P, Zaragoza R, Viña JR and
Lluch A: Triple-negative breast cancer: Molecular features,
pathogenesis, treatment and current lines of research. Cancer Treat
Rev. 36:206–215. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hayes J, Peruzzi PP and Lawler S:
MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol
Med. 20:460–469. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Iorio MV, Ferracin M, Liu CG, Veronese A,
Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M,
et al: MicroRNA gene expression deregulation in human breast
cancer. Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Blenkiron C, Goldstein LD, Thorne NP,
Spiteri I, Chin SF, Dunning MJ, Barbosa-Morais NL, Teschendorff AE,
Green AR, Ellis IO, et al: MicroRNA expression profiling of human
breast cancer identifies new markers of tumor subtype. Genome Biol.
8:R2142007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Teoh SL and Das S: The role of MicroRNAs
in diagnosis, prognosis, metastasis and resistant cases in breast
cancer. Curr Pharm Des. 23:1845–1859. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li P, Xu T, Zhou X, Liao L, Pang G, Luo W,
Han L, Zhang J, Luo X, Xie X and Zhu K: Downregulation of miRNA-141
in breast cancer cells is associated with cell migration and
invasion: Involvement of ANP32E targeting. Cancer Med. 6:662–672.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Buffa FM, Camps C, Winchester L, Snell CE,
Gee HE, Sheldon H, Taylor M, Harris AL and Ragoussis J:
microRNA-associated progression pathways and potential therapeutic
targets identified by integrated mRNA and microRNA expression
profiling in breast cancer. Cancer Res. 71:5635–5645. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bockhorn J, Dalton R, Nwachukwu C, Huang
S, Prat A, Yee K, Chang YF, Huo D, Wen Y, Swanson KE, et al:
MicroRNA-30c inhibits human breast tumour chemotherapy resistance
by regulating TWF1 and IL-11. Nat Commun. 4:13932013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang N, Wang X, Huo Q, Sun M, Cai C, Liu
Z, Hu G and Yang Q: MicroRNA-30a suppresses breast tumor growth and
metastasis by targeting metadherin. Oncogene. 33:3119–3128. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
De Craene B and Berx G: Regulatory
networks defining EMT during cancer initiation and progression. Nat
Rev Cancer. 13:97–110. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Foulkes WD, Smith IE and Reis-Filho JS:
Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lin S and Gregory RI: MicroRNA biogenesis
pathways in cancer. Nat Rev Cancer. 15:321–333. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Radojicic J, Zaravinos A, Vrekoussis T,
Kafousi M, Spandidos DA and Stathopoulos EN: MicroRNA expression
analysis in triple-negative (ER, PR and Her2/neu) breast cancer.
Cell Cycle. 10:507–517. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mathe A, Scott RJ and Avery-Kiejda KA:
MiRNAs and other epigenetic changes as biomarkers in triple
negative breast cancer. Int J Mol Sci. 16:28347–28376. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cascione L, Gasparini P, Lovat F, Carasi
S, Pulvirenti A, Ferro A, Alder H, He G, Vecchione A, Croce CM, et
al: Integrated microRNA and mRNA signatures associated with
survival in triple negative breast cancer. PLoS One. 8:e559102013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Agrawal R, Tran U and Wessely O: The
miR-30 miRNA family regulates Xenopus pronephros development and
targets the transcription factor Xlim1/Lhx1. Development.
136:3927–3936. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Baffa R, Fassan M, Volinia S, O'Hara B,
Liu CG, Palazzo JP, Gardiman M, Rugge M, Gomella LG, Croce CM and
Rosenberg A: MicroRNA expression profiling of human metastatic
cancers identifies cancer gene targets. J Pathol. 219:214–221.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kao CJ, Martiniez A, Shi XB, Yang J, Evans
CP, Dobi A, deVere White RW and Kung HJ: miR-30 as a tumor
suppressor connects EGF/Src signal to ERG and EMT. Oncogene.
33:2495–2503. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao JJ, Lin J, Zhu D, Wang X, Brooks D,
Chen M, Chu ZB, Takada K, Ciccarelli B, Admin S, et al: miR-30-5p
functions as a tumor suppressor and novel therapeutic tool by
targeting the oncogenic Wnt/β-catenin/BCL9 pathway. Cancer Res.
74:1801–1813. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cheng CW, Wang HW, Chang CW, Chu HW, Chen
CY, Yu JC, Chao JI, Liu HF, Ding SL and Shen CY: MicroRNA-30a
inhibits cell migration and invasion by downregulating vimentin
expression and is a potential prognostic marker in breast cancer.
Breast Cancer Res Treat. 134:1081–1093. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang J, Zhang H, Liu J, Tu X, Zang Y, Zhu
J, Chen J, Dong L and Zhang J: miR-30 inhibits TGF-β1-induced
epithelial-to-mesenchymal transition in hepatocyte by targeting
Snail1. Biochem Biophys Res Commun. 417:1100–1105. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kumarswamy R, Mudduluru G, Ceppi P,
Muppala S, Kozlowski M, Niklinski J, Papotti M and Allgayer H:
MicroRNA-30a inhibits epithelial-to-mesenchymal transition by
targeting Snai1 and is downregulated in non-small cell lung cancer.
Int J Cancer. 130:2044–2053. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Borcherding N, Kusner D, Liu GH and Zhang
W: ROR1, an embryonic protein with an emerging role in cancer
biology. Protein Cell. 5:496–502. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
O'Connell MP, Marchbank K, Webster MR,
Valiga AA, Kaur A, Vultur A, Li L, Herlyn M, Villanueva J, Liu Q,
et al: Hypoxia induces phenotypic plasticity and therapy resistance
in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer
Discov. 3:1378–1393. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhou JK, Zheng YZ, Liu XS, Gou Q, Ma R,
Guo CL, Croce CM, Liu L and Peng Y: ROR1 expression as a biomarker
for predicting prognosis in patients with colorectal cancer.
Oncotarget. 8:32864–32872. 2017.PubMed/NCBI
|
|
29
|
Balakrishnan A, Goodpaster T,
Randolph-Habecker J, Hoffstrom BG, Jalikis FG, Koch LK, Berger C,
Kosasih PL, Rajan A, Sommermeyer D, et al: Analysis of ROR1 protein
expression in human cancer and normal tissues. Clin Cancer Res.
23:3061–3071. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang S, Cui B, Lai H, Liu G, Ghia EM,
Widhopf GF II, Zhang Z, Wu CC, Chen L, Wu R, et al: Ovarian cancer
stem cells express ROR1, which can be targeted for
anti-cancer-stem-cell therapy. Proc Natl Acad Sci USA.
111:17266–17271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hojjat-Farsangi M, Moshfegh A,
Daneshmanesh AH, Khan AS, Mikaelsson E, Osterborg A and Mellstedt
H: The receptor tyrosine kinase ROR1-an oncofetal antigen for
targeted cancer therapy. Semin Cancer Biol. 29:21–31. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gentile A, Lazzari L, Benvenuti S,
Trusolino L and Comoglio PM: The ROR1 pseudokinase diversifies
signaling outputs in MET-addicted cancer cells. Int J Cancer.
135:2305–2316. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang S, Chen L, Wang-Rodriguez J, Zhang
L, Cui B, Frankel W, Wu R and Kipps TJ: The onco-embryonic antigen
ROR1 is expressed by a variety of human cancers. Am J Pathol.
181:1903–1910. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cui B, Zhang S, Chen L, Yu J, Widhopf GF
II, Fecteau JF, Rassenti LZ and Kipps TJ: Targeting ROR1 inhibits
epithelial-mesenchymal transition and metastasis. Cancer Res.
73:3649–3660. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chien HP, Ueng SH, Chen SC, Chang YS, Lin
YC, Lo YF, Chang HK, Chuang WY, Huang YT, Cheung YC, et al:
Expression of ROR1 has prognostic significance in triple negative
breast cancer. Virchows Arch. 468:589–595. 2016. View Article : Google Scholar : PubMed/NCBI
|
